Dosing & Uses
Dosage Forms & Strengths
topical cream
- 0.025%
- 0.035%
- 0.075%
- 0.1%
topical gel
- 0.025%
topical liquid
- 0.025%
Skeletomuscular Pain
Apply to affected area TID or QID for 3-4 consecutive weeks and evaluate efficacy; efficacy decreased if used <3 times daily; not to exceed 4 applications/day; wash hands with soap and water after applying
Diabetic Neuropathy (Off-label)
Cream: Apply to affected area TID/QID times daily for 3-4 consecutive weeks and evaluate efficacy; not to exceed 4 applications/day; wash hands with soap and water after applying
Orphan Indications
Painful HIV-associated neuropathy
Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis
Postherpetic neuralgia
Erythromelalgia
Orphan indication sponsors
- NeurogesX, Inc; San Carlos Business Park 981F Industrial Road; San Carols, CA 94070-4117
- Vallinex Incorporated; 2400 Boston Street, Suite 330; Baltimore, MD 21224
- TheraQuest Biosciences, LLC; 146 Medinah Drive; Blue Bell, PA 19422-3212
Safety and efficacy not established
Adverse Effects
>10%
Transient increased pain at application site (dissipates w/ continued use)
Application site erythema (63%)
Pain (42%)
1-10%
Nausea (5%)
Vomiting (3%)
Hypertension (2%)
Dryness (2%)
Swelling (2%)
Pruritus (6%)
Papules (6%)
Edema (4%)
Sinusitis (3%)
Bronchitis (2%)
<1%
Exfoliation
Dizziness
Cough
Skin odor
Headache
Dysguesia
Warnings
Contraindications
Hypersensitivity
Self-medication: Use on wounds; concurrent use with other topical analgesics; damaged, irritated, broken skin or application into skin folds; within one our before or after bath, hot tub, sauna, or shower; do not cover with bandage; not for use with external heat source, including heating pad
Cautions
For external use only
Do not apply to face or scalp to avoid exposure to eyes or mucous membranes
Transient burn sensation may occur but generally disappears after several days
Not for use immediately before or after activities such as, swimming, showering, bathing, strenuous exercise, sunbathing, sauna, steam bath, or other types of heat, or exposure to sunlight to treated areas
Accidental exposure to eyes and mucous membranes can occur from touching drug product or items exposed to drug product and then touching eyes and mucous membranes
If irritation of eyes or mucous membranes occurs, flush eyes and mucous membranes with cool water
First, to third-degree chemical Burns may occur upon application; discontinue use and seek medical attention if signs of skin injury, including pain, blistering, or swelling occurs
Contact healthcare professional if excessive redness, blistering, burning or irritation develops, symptoms persist for >7 days, symptoms get worse, symptoms resolve and then recur, or if difficulty breathing or swallowing occurs
Do not handle contact lenses for at least 1 hr after handling drug product
Use caution in patients with uncontrolled hypertension, history of cerebrovascular events
Pregnancy & Lactation
Pregnancy Category: B
Lactation: Unknown whether distributed in breast milk; do not apply to nipple or areola
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Transient receptor potential vanilloid-1 (TRPV1) agonist; topical application causes initial TRPV1 stimulation that may cause pain, followed by pain relief by reduction in TRPV1-expressing nociceptive nerve endings
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Capzasin topical - | 0.025-10 % gel | ![]() | |
Capzasin topical - | 0.15 % liquid | ![]() | |
Medicated Heat Patch topical - | 0.025 % transdermal system | ![]() | |
Arthritis Pain Relief (capsaicin) topical - | 0.1 % cream | ![]() | |
Zostrix-HP topical - | 0.1 % cream | ![]() | |
Capsimide topical - | 0.025 % transdermal system | ![]() | |
capsaicin topical - | 0.025 % cream | ![]() |
Copyright © 2010 First DataBank, Inc.